Search Results
10
Everything
ITM Appoints Dr. Celine Wilke as Chief Medical Officer
April 01, 2025 05:00 ET
|
ITM Isotope Technologies Munich SE
Experienced leader in radiopharmaceutical drug development, regulatory, and clinical strategies will advance ITM’s broad pipeline and clinical development strategy Garching / Munich, Germany, April...
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 27, 2025 16:05 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
March 27, 2025 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Industry experts see the global radiotherapy market continuing to grow in the years to come. A recent report...
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
March 20, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Robotic Radiotherapy Market Report 2024-2034: Lucrative Opportunities in Emerging Markets, Partnerships and Collaborations, & Personalized Medicine
March 04, 2025 10:21 ET
|
Research and Markets
Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Robotic Radiotherapy Market by Product, by Technology, by Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
ITM to Present Top Line Results from Phase 3 COMPETE Trial with [177Lu]Lu-edotreotide for the Treatment of Grade 1 & Grade 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at European Neuroendocrine Tumor Society (ENETS) Conference
February 25, 2025 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 25 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will provide topline data results from its Phase...
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
February 24, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 20, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
ITM to Present at Raymond James Private Biotech Symposium
February 18, 2025 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...